Neuralstem Inc. (NASDAQ:CUR) CEO Richard J. Daly purchased 35,715 shares of the business’s stock in a transaction dated Friday, November 25th. The shares were purchased at an average price of $0.28 per share, for a total transaction of $10,000.20. Following the acquisition, the chief executive officer now owns 102,680 shares of the company’s stock, valued at $28,750.40. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Neuralstem Inc. (NASDAQ:CUR) opened at 0.2841 on Wednesday. Neuralstem Inc. has a 12 month low of $0.19 and a 12 month high of $1.20. The company’s market cap is $32.60 million. The company’s 50-day moving average is $0.28 and its 200-day moving average is $0.29.

Neuralstem (NASDAQ:CUR) last announced its quarterly earnings data on Tuesday, November 8th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by $0.02. Neuralstem had a negative net margin of 170,366.66% and a negative return on equity of 4,420.33%. On average, equities research analysts expect that Neuralstem Inc. will post ($0.19) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Richard J. Daly Purchases 35,715 Shares of Neuralstem Inc. (CUR) Stock” was originally published by Financial Market News and is the sole property of of Financial Market News. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The original version of this piece can be accessed at

A number of large investors have recently made changes to their positions in CUR. Blair William & Co. IL bought a new stake in shares of Neuralstem during the second quarter worth $122,000. Vanguard Group Inc. raised its stake in shares of Neuralstem by 21.8% in the second quarter. Vanguard Group Inc. now owns 3,384,138 shares of the company’s stock worth $984,000 after buying an additional 606,500 shares during the last quarter. Finally, Sabby Management LLC bought a new stake in shares of Neuralstem during the second quarter worth $1,893,000. Institutional investors own 10.77% of the company’s stock.

A number of research firms have recently commented on CUR. Brean Capital began coverage on shares of Neuralstem in a report on Tuesday, October 4th. They set a “buy” rating and a $4.00 price target on the stock. Roth Capital reiterated a “buy” rating and set a $1.20 price target on shares of Neuralstem in a report on Friday, September 23rd. Finally, Aegis began coverage on shares of Neuralstem in a report on Monday, November 7th. They set a “buy” rating on the stock.

Neuralstem Company Profile

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

5 Day Chart for NASDAQ:CUR

Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with's FREE daily email newsletter.